For drug companies, IP is fairly straightforward. In digital therapeutics, the answer is not so clear cut. Listen as Jenny Barnett and Neil Tiwari discuss how IP in digital therapeutics is only one pillar for success.
Jennifer Barnett – Chief Scientific Officer, Cambridge Cognition (LinkedIn)
Other videos with Jennifer
Neil Tiwari – General Partner, dRx Capital (LinkedIn)
Other videos with Neil